Insider Selling: Aduro Biotech, Inc. (NASDAQ:ADRO) CEO Sells $487,600.00 in Stock

Aduro Biotech, Inc. (NASDAQ:ADRO) CEO Stephen T. Isaacs sold 40,000 shares of the stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $12.19, for a total value of $487,600.00. Following the completion of the transaction, the chief executive officer now owns 144,025 shares of the company’s stock, valued at $1,755,664.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Stephen T. Isaacs also recently made the following trade(s):

  • On Tuesday, May 16th, Stephen T. Isaacs sold 16,673 shares of Aduro Biotech stock. The stock was sold at an average price of $10.00, for a total value of $166,730.00.
  • On Monday, May 15th, Stephen T. Isaacs sold 10,600 shares of Aduro Biotech stock. The stock was sold at an average price of $10.01, for a total value of $106,106.00.
  • On Tuesday, May 16th, Stephen T. Isaacs sold 27,273 shares of Aduro Biotech stock. The stock was sold at an average price of $10.01, for a total value of $273,002.73.

Shares of Aduro Biotech, Inc. (NASDAQ:ADRO) opened at 11.35 on Friday. The firm has a 50-day moving average price of $12.44 and a 200-day moving average price of $10.98. The firm’s market capitalization is $846.85 million. Aduro Biotech, Inc. has a 1-year low of $8.75 and a 1-year high of $16.15.

Aduro Biotech (NASDAQ:ADRO) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.02. Aduro Biotech had a negative return on equity of 43.92% and a negative net margin of 609.58%. The company had revenue of $5.90 million for the quarter, compared to the consensus estimate of $3.98 million. During the same period in the previous year, the business posted $0.03 EPS. The business’s revenue for the quarter was down 84.9% on a year-over-year basis. On average, analysts forecast that Aduro Biotech, Inc. will post ($1.37) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally published by Stock Observer and is owned by of Stock Observer. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.thestockobserver.com/2017/08/12/insider-selling-aduro-biotech-inc-nasdaqadro-ceo-sells-487600-00-in-stock.html.

Several institutional investors have recently modified their holdings of ADRO. Legal & General Group Plc boosted its position in shares of Aduro Biotech by 11.2% in the second quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 1,043 shares during the last quarter. Quantitative Systematic Strategies LLC bought a new position in shares of Aduro Biotech during the first quarter valued at approximately $145,000. Daiwa SB Investments Ltd. bought a new position in shares of Aduro Biotech during the first quarter valued at approximately $153,000. Creative Planning boosted its position in shares of Aduro Biotech by 73.9% in the first quarter. Creative Planning now owns 15,000 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 6,375 shares during the last quarter. Finally, Parametric Portfolio Associates LLC boosted its position in shares of Aduro Biotech by 15.9% in the first quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock valued at $166,000 after buying an additional 2,119 shares during the last quarter. 35.60% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts recently weighed in on the company. Canaccord Genuity set a $30.00 price objective on Aduro Biotech and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Zacks Investment Research lowered Aduro Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. BidaskClub lowered Aduro Biotech from a “hold” rating to a “sell” rating in a research report on Tuesday. HC Wainwright set a $18.00 price objective on Aduro Biotech and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Finally, Cowen and Company started coverage on Aduro Biotech in a research report on Tuesday, July 18th. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. Aduro Biotech currently has a consensus rating of “Buy” and a consensus price target of $19.00.

Aduro Biotech Company Profile

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply